Forty-year journey of angiogenesis translational research.

Abstract

Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.

• Authors: Yihai Cao, Jack Arbiser, Robert J D'Amato, Patricia A D'Amore, Donald E Ingber, Robert Kerbel, Michael Klagsbrun, Sharon Lim, Marsha A Moses, Bruce Zetter, Harold Dvorak, Robert Langer
• Journal: Science translational medicine (Sci Transl Med) Vol. 3 Issue 114 Pg. 114rv3 (Dec 21 2011) ISSN: 1946-6242 [Electronic] United States
• PMID: 22190240 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Biomarkers
• Vascular Endothelial Growth Factor A
• Fibroblast Growth Factor 2

Topics

• Biomarkers
• Fibroblast Growth Factor 2 (physiology)
• Humans
• Neoplasms (blood supply)
• Neovascularization, Pathologic (drug therapy)
• Vascular Endothelial Growth Factor A (physiology)